Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

BACKGROUND: Ixekizumab improves signs/symptoms of psoriatic arthritis (PsA). We present an integrated analysis of baseline disease burden and post-baseline outcomes in ixekizumab-treated patients with enthesitis or dactylitis. METHODS: Data from SPIRIT-P1 and SPIRIT-P2 were integrated. Patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gladman, Dafna D., Orbai, Ana-Maria, Klitz, Uta, Wei, James Cheng-Chung, Gallo, Gaia, Birt, Julie, Rathmann, Suchitrita, Shrom, David, Marzo-Ortega, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350390/
https://www.ncbi.nlm.nih.gov/pubmed/30696483
http://dx.doi.org/10.1186/s13075-019-1831-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350390/
https://www.ncbi.nlm.nih.gov/pubmed/30696483
http://dx.doi.org/10.1186/s13075-019-1831-0

Ejemplares similares